Kolon Life Science succeeds in exporting ‘Invossa’ technology for KRW 500 billion

Kolon Life Science(CEO Woo-Seok Lee) will export technology of the world’s first cell and gene therapy for degenerative arthritis, ‘Invossa,’ to Japan. This is the result of Invossa’s safety and efficacy recognized in the international market in the progress of the final examination for its product approval at the Ministry of Food and Drug Safety after completing its Phase 3 clinical trial in K...